IGF-1 LR3 (Metabolic)

IGF-1 LR3 (Metabolic) Metabolic & Systemic Energy Profile

IGF-1 LR3 (Metabolic) is fundamentally integrated into the modulation of mammalian metabolism, forcing biological networks toward lipolysis, enhanced ATP synthesis, and profound systemic energy mobilization.

Pharmacological Architecture

Parameter	Value
Molecular Formula	C400H625N111O115S6
Molecular Mass	9111.6 g/mol
Assay Purity	>98.0%
Appearance	Lyophilized white solid

Figure 1: Cellular Action of IGF-1 LR3 (Metabolic)

Metabolic Transduction Pattern

Detailed cascade of actions governing its systemic thermogenic profile:

1. Engineered explicitly as a heavily modified variant of Insulin-like Growth Factor 1.
2. Features an arginine substitution at the 3rd position and a 13-amino-acid extension.
3. Completely evades the binding proteins (IGFBP) that traditionally deactivate raw IGF-1.
4. Forces systemic, sustained cellular hyperplasia (the splitting and creation of brand new cells).
5. Drives raw glucose and severe amino acid payloads directly into skeletal muscle tissue.

Figure 2: Rate of Systemic Lipolysis & Output

Primary Research Results

• Outcome 1: Considered astronomically more potent (up to 3x) and longer-lasting than endogenous IGF-1.
• Outcome 2: Represents the absolute pinnacle pathway for forcing new muscle cell formation.
• Outcome 3: Prolonged half-life (20-30 hours) provides an immense metabolic 'feeding ring' throughout the body.

Long-Acting IGF-1 for Metabolic Research

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified 83-amino acid analogue of native IGF-1 in which glutamic acid at position 3 is replaced with arginine (Arg3) and a 13-amino acid N-terminal extension is added. These modifications dramatically reduce binding to IGF-binding proteins (IGFBPs 1-6), which normally sequester 95–99% of circulating IGF-1. The result is a peptide with approximately 2–3 times the potency of native IGF-1 due to vastly increased free (bioavailable) concentration and an extended half-life of 20–30 hours versus 12–15 hours for native IGF-1.

1. IGF-1 LR3 binds the IGF-1 receptor (IGF-1R) with affinity comparable to native IGF-1, activating the canonical PI3K/Akt and Ras/MAPK signaling cascades.
2. Reduced IGFBP binding means that virtually 100% of administered IGF-1 LR3 is bioavailable, compared to only 1–5% of native IGF-1.
3. PI3K/Akt activation stimulates GLUT4 translocation to the cell membrane in skeletal muscle and adipose tissue, increasing glucose uptake independently of insulin.
4. In skeletal muscle, IGF-1R signaling activates the mTOR/p70S6K pathway, promoting protein synthesis and muscle hypertrophy.
5. In adipose tissue, IGF-1R activation promotes glucose oxidation and inhibits lipolysis at high concentrations, though the net metabolic effect depends on tissue-specific receptor density.

Metabolic Research Applications

• Insulin Sensitization: IGF-1 LR3 improves whole-body insulin sensitivity by activating glucose disposal pathways that are partially independent of insulin receptor signaling.
• Hypoglycemia Risk: The insulin-like metabolic effects of IGF-1 LR3 carry significant hypoglycemia risk, particularly at higher doses. Blood glucose monitoring is essential in all research protocols.
• Body Composition: Concurrent anabolic (muscle) and metabolic (glucose disposal) effects make IGF-1 LR3 a research tool for studying nutrient partitioning between lean and fat mass.
• Dosing Distinction: Metabolic research protocols typically use lower systemic doses than growth-focused protocols, as the glucose-lowering threshold is below the anabolic threshold.
• Storage: Reconstitute in sterile water or acetic acid (0.1 M) for stability. Refrigerate at 2–8°C after reconstitution. Avoid freeze-thaw cycles.